Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Transcenta to Start Phase II Trial of Osteoporosis Therapy in China

publication date: Jul 31, 2023

Transcenta Holding of Suzhou was approved to start a China Phase II trial of blosozumab, an anti-sclerostin mAb, to treat osteoporosis. The candidate is expected to have anabolic and anti-resorptive effects, stimulating bone formation while inhibiting bone absorption. The trial will enroll patients with reduced bone mineral density, who will receive either a single IV dose or multiple doses over one year. Transcenta notes that no anti-sclerostin therapies are available in China, though Amgen’s anti-sclerostin, Evenity (romosozumab), is approved in the US, EU and Japan. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital